Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

Patients 60 to 70 years of age with newly diagnosed multiple myeloma were prospectively randomized between 4 cycles of anthracycline/dexamethasone-based induction chemotherapy (A1) or only 2 x 4 days of dexamethasone (A2). A reference arm included patients who could not be randomized (B). Tandem melphalan 140 mg/m² (MEL140) with autologous transplantation was scheduled for all patients.

Sex

All

Minimum age

60 Years

Maximum age

70 Years

Inclusion Criteria:

* Histological confirmed multiple myeloma stage II or III according to the classification of Salmon and Durie
* Aged between 60 and 70 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Signed and dated written informed consent
* No previous chemotherapy or not more than one cycle in total or previous chemotherapy of more than one cycle if paused for at least 6 months and not more than six cycles in total (arm A1 and A2 only)
* Ongoing primary chemotherapy of two to maximum six cycles (arm B only)

Exclusion Criteria:

* Multiple myeloma stage I according to the classification of Salmon and Durie without need of any therapy
* Aged under 60 or over 70 years
* ECOG performance status \>2
* Previous chemotherapy of more than six cycles
* Informed consent missing
* Myocardial infarction within the last six months
* Cardiac dysrhythmia stage IV b according to the classification of Lown
* Heart failure \>NYHA II according to the classification of the New York Heart Association (NYHA), left ventricular ejection fraction \<50% in ECG
* Severe restrictive or obstructive pulmonary disease (diffusing capacity \<60% under normal)
* Renal insufficiency including a serum creatinine level \>2mg/dl if not caused by multiple myeloma and reversible
* Liver diseases combined with an elevation of transaminases and of bilirubin of three times above normal
* Severe infections (HIV, hepatitis B/C, syphilis etc. )
* Severe psychiatric disease
* Other not curative treated malignant tumor within the last five years
* Concurrent participation in other clinical studies
* Other not curative treated malignant tumor within the last five years

• BACKGROUNDBlade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23. doi: 10.1046/j.1365-2141.1998.00930.x. No abstract available. PMID 9753033
• BACKGROUNDAlexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990 Feb;33(2):86-9. doi: 10.1002/ajh.2830330203. PMID 2301376
• BACKGROUNDClark AD, Douglas KW, Mitchell LD, McQuaker IG, Parker AN, Tansey PJ, Franklin IM, Cook G. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment. Br J Haematol. 2002 Jun;117(3):605-12. doi: 10.1046/j.1365-2141.2002.03519.x. PMID 12028028
• BACKGROUNDStraka C, Hebart H, Adler-Reichel S, Werding N, Emmerich B, Einsele H. Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma. Oncology. 2003;65 Suppl 2:94-8. doi: 10.1159/000073368. PMID 14586157
• BACKGROUNDSzelenyi H, Kreuser ED, Keilholz U, Menssen HD, Keitel-Wittig C, Siehl J, Knauf W, Thiel E. Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. Ann Oncol. 2001 Jan;12(1):105-8. doi: 10.1023/a:1008362107080. PMID 11249035
• DERIVEDStraka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke C, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf HH, Sezer O, Bargou R, Jung W, Trumper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schafer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016 Nov;101(11):1398-1406. doi: 10.3324/haematol.2016.151860. Epub 2016 Aug 4.